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Abstract 
Objectives: To determine the barriers to clinic attendance and pill taking for PLHIV in rural 
Zambia.  
Methods: This analysis uses baseline data from a 2015 cross sectional livelihood pilot study for 
PLHIV in rural Zambia. Univariate and bivariate analysis was conducted in Stata.  
Results: Most people in this study are not experiencing barriers to clinic attendance and pill 
taking. The most commonly experienced barriers to clinic attendance are related to time and 
distance to the clinic. Bivariable results indicated significant association between education, 
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minutes of travel time to clinic, self efficacy and barriers to clinic attendance as well as 
associations between self perceived health and barriers to pill taking.  
Conclusion: Interventions should be targeted toward rural, young populations with limited 
education. Further research is recommended on barriers to pill taking and clinic attendance, and 
self-efficacy.  
Acronyms & Abbreviations 
• AIDS: Acquired Immuno Deficiency Syndrome  
• ART: Antiretroviral Therapy 
• HIV: Human Immunodeficiency Virus  
• LMIC: Low and Middle Income Countries  
• PLHIV: People Living With HIV 
Introduction  
Introduction  
In 2015 it was estimated that there were 36.9 million people living with Human 
Immunodeficiency Virus (HIV) and Acquired Immuno Deficiency Syndrome (AIDS) worldwide 
(UNAIDS, 2015). Of this total, 1.2 million were living in Zambia, ranking the nation 6th in sub-
Saharan Africa in prevalence of HIV infections among adults age 15-49 (Sasaki et al., 2012; 
UNAIDS, 2015). The prevalence of HIV in Zambia has decreased from 16% of adults in 2001-
2002 to 13% in 2014. However, even with this reduction the high infection rates have a profound 
impact on individual lives as well as overall community well-being (Central Statistics Office, 
Ministry of Health, and ICF, 2014).  
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In 1996, antiretroviral therapy (ART) was introduced as part of the strategy to reduce 
HIV/AIDS related deaths. As of 2015, there were 18.5 million people using ART globally 
(Gupta et al., 2012; Kaiser Family Foundation, 2015; UNAIDS, 2015). There has been an overall 
increase in access to ART by 84% in the last 10 years and an even larger increase in low- and 
middle-income countries (LMICs) (UNAIDS, 2015). There were 8 million people on ART in 
LMICs in 2011, which is a 20-fold increase of ART access since 2003 (Gupta et al., 2012; 
UNAIDS, 2015; UNAIDS, 2012). Although ART access is already noted as a significant global 
public health achievement, the World Health Organization (WHO) aims to accelerate treatment 
access to all PLHIV (World Health Organization, 2015). 
ART access is essential to addressing the HIV epidemic but must also be coupled with 
ART adherence to reduce virus mutation and medication resistance. The research question for 
this study is what are the barriers and frequency of occurrence to clinic attendance and pill taking 
for PLHIV in rural Zambia. Additionally, the research examines bivariate associations between 
patient characteristics and their reported barriers to clinic attendance and pill taking. If we are 
able to determine the barriers to ART adherence then we can design HIV treatment interventions 
that are well suited to helping patients and medial systems achieve optimum adherence. This 
research contributes to the emerging literature on barriers to ART adherence among PLHIV in 
rural Zambia.  
Antiretroviral Therapy & Adherence 
HIV makes it difficult for the body to fight diseases (Government of the Republic of 
Zambia, 2010). The virus replicates quickly and overwhelms the immune system so that 
eventually the body is no longer able to fight off opportunistic infections (Government of the 
Republic of Zambia, 2010). When it reaches that point, it is classified as  the advanced stage of 
HIV infection or Acquired Immune Deficiency Syndrome (AIDS) (Government of the Republic 
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of Zambia, 2010). HIV is spread through bodily fluids and can be prevented through use of 
condoms, sterile needles and tested blood transfusions (Government of the Republic of Zambia, 
2010).  
Antiretroviral therapy (ART) is a combination of antiretroviral medications that control 
the HIV virus (Government of the Republic of Zambia, 2010). ART was introduced in the 
Zambian private sector in 2002 and expanded to the public sector in 2005 (Moomba, 2012). ART 
is administered to people living with HIV to slow progression of HIV to AIDS, reduce mortality, 
improve well-being and prevent new infections (Akilleswaran et al., 2005; Amberbir et al., 2008; 
Farmer et al., 2001; Lawn et al., 2008). ART must be taken correctly 95% of the time to prevent 
virus replication and mutation that ultimately leads to medication resistance (Bangsberg et al., 
2001; Government of the Republic of Zambia, 2010; Kaiser Family Foundation, 2015; Muya et 
al., 2014; Yaya et al., 2014). Medication resistance means that the ART medicine combination is 
no longer effective on suppressing HIV and a new combination must be administered 
(Government of the Republic of Zambia, 2010). ART medicine combination options are limited 
and they increase in price as well as side effects as patients move from first line regimens to 
newer ones (Government of the Republic of Zambia, 2010). This is a challenge for an individual 
but it can also impact a community because the new ART resistant strain of HIV can be 
transmitted from person to person, meaning that those with new infections may struggle to find 
effective and affordable ART (Government of the Republic of Zambia, 2010; Gupta et al., 2012).  
Pill taking is defined as the ingestion of ART medication as per medical provider 
recommendations (for example, accurate dose, timetable, and nutrition) where as clinic 
attendance is defined as going to a medical facility for medical check ups and prescription refills. 
Together these elements make up ART adherence (Bangsberg et al, 2001; DiMatteo, 2004). 
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Often research only considers pill taking rather than the broader multi-dimensional elements of 
adherence. Therefore, in this study, adherence is broken down into the actions of clinic 
attendance and pill taking to try and understand multiple influences impacting adherence for 
PLHIV in rural Zambia.  
A patient is considered to be adherent to their ART medication if they follow provider 
recommendations (schedule, nutrition, etc.) for their medication regimen ≥95% of the time 
(Amberbir et al., 2008). Rates of ART adherence vary worldwide and are reported to be between 
50-94% in sub-Saharan Africa (Amberbir et al., 2008; Chesney, 2000; DiMatteo, 2004; Gill et 
al., 2005; Oku et al., 2013; Orrel et al, 2003; Yaya et al., 2014). These rates are reportedly on par 
or better than those in resource-adequate countries (DiMatteo, 2004; Hardon et al., 2007; Orrel et 
al., 2003). A study in rural Zambia showed that 60% of patients achieved full adherence at 6 
weeks by never skipping doses and following the time requirements of their recommended ART 
regimen (Sasaki et al., 2012).  
Barriers to Pill Taking and Clinic Attendance  
Adherence is a dynamic process so it is important to identify and address factors that 
influence PLHIV’s ability to adhere to ART, which in turn, improves their health and reduces 
ART resistance (Amberbir et al., 2008). Prior research indicates that adherence is influenced by 
numerous factors including age, gender, education, socioeconomic status, and psychosocial 
factors (Amberbir et al., 2008; DiMatteo, 2004). Many barriers to adherence are applicable to 
both clinic attendance and pill taking such as stigma, poor health information, low education 
levels, and transportation costs (Hardon et al, 2007; Moomba, 2012; Muya et al., 2014). For 
example, if a PLHIV is unable to afford transportation to visit the clinic they may not be able to 
get a prescription for the appropriate ART and/or collect pills from the pharmacy. Although 
factors associated with adherence are consistent across multiple studies, it is important to note 
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that there are some studies that have shown conflicting information regarding the relationship 
between socio-demographics and ART adherence (Amberbir et al., 2008). For example, gender 
and age do not have a consistent strength or direction of association with adherence (DiMatteo, 
2004).  
The barriers unique to clinic attendance are usually related to cost and time. For example, 
travel time to the clinic and wait times at the clinic are often a barriers to clinic attendance 
(Hardon et al, 2007; Moomba, 2012; Muya et al., 2014). Additionally, while antiretroviral drugs 
are often free, other costs (for example, transport and missed income opportunities) prevent 
PLHIV from adhering to ART (Hardon et al, 2007). Barriers unique to pill taking include 
complexity of regimen, food insecurity, stigma, forgetfulness, feeling ill, being busy, lack of 
appropriate counseling, medication side effects, running out of medication and medication/food 
demands (Amberbir et al., 2008; Hardon et al., 2007; Moomba, 2012; Muya et al., 2014). 
Research Methods 
Data and Sample  
 The study was cross sectional and examined ART adherence, access to food, dietary intake, 
income and expenditures, and psychosocial outcomes (e.g., self-efficacy and hope for the future). 
The study used baseline data from a pilot livelihood study for PLHIV in rural Zambia, which 
was collected in 2015 by interviewer-administered survey. Participants for the study were 
randomly selected from ART enrollment patient lists at two health centers within Lundazi 
District, Eastern Province, Zambia. Each health center recruited approximately 50 patients to 
participate in the study for a total of 101 participants. Inclusion criteria specified that subjects be 
at least 18 but no older than 40 years of age, economically poor, male or female, HIV positive, 
and currently receiving outpatient medical care and ART at either Lundazi District Hospital or 
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Lumezi Mission Hospital. Economically poor is defined as individuals who are living below the 
Zambian national poverty threshold (475,000 Zambian kwachas or $131 USD annually). The 
economic and age criteria were set to capture persons more likely to participate in a 
microenterprise as part of the study. Persons under 18 are likely to be economically dependent on 
their parents and/or attending school and persons older than 40 are less economically active in 
Zambia.  
Data were collected using a survey to capture demographic information such as age, sex, 
marital status, ethnic group, religious group, school, occupation, monthly income, water source, 
fuel source, dwelling materials, general health and distance from home to the health facility in 
minutes/kilometers. Outcome variables such as barriers to clinic attendance and pill taking were 
collected through a series of questions on the same survey. The study was approved by IRBs at 
the University of North Carolina at Chapel Hill and the University of Zambia. Written consent 
was obtained from all study participants.    
Measures  
Outcome Variables. The barriers to pill taking and clinic attendance for PLHIV were 
measured using the “Structural Barriers to Clinical Attendance” (SBCA) and “Structural Barriers 
to Medication Taking” (SBMT) instruments (Coetzee & Kagee, 2013). Coetzee and Kagee 
developed these as new scaled instruments for barriers to clinic attendance and medication taking 
in sub- Saharan Africa. SBCA and SBMT ask ART patients to identify the extent to which 
structural barriers to clinic attendance and pill taking apply to their own circumstances. For 
example, “I do not attend my clinic appointments because the clinic is too far from the bus 
stop/taxi rank” or “I have difficulty taking my ART pills because I do not always have food with 
which to take them.” “A Likert-type scale ranging from 1 to 5 was provided where 1 indicated 
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“Never”, 2 indicated “Rarely”, 3 indicated “some of the time”, 4 indicated “most of the time”, 
and 5 indicated “always” (Coetzee & Kagee, 2013). Each outcome includes a set of 12 questions.  
Explanatory Variables. Self-efficacy was measured through a series of likert scale 
questions about confidence in ART treatment adherence for the past month. For example, “In the 
past month, how confident have you been that you can stick to your treatment plan even when 
side effects begin to interfere with daily activities?” or “In the past month, how confident have 
you been that you can integrate your treatment into your daily routine?” The likert scale 
responses were on a scale from 0-9 with 0 being, “Cannot do it at all” and 9 being, “ Certain can 
do it” (Johnson et al., 2007). Perceived stress was measured through a series of likert scale 
questions about feelings and thoughts during the last month. For example, “In the last month, 
how often have you been upset because of something that happened unexpectedly?” or “In the 
last month, how often have you felt that you were unable to control the important things in your 
life?” The likert scale responses were on a scale from 0-4 with 0 being, “Never” and 4 being, 
“Always.” 
Analysis Plan 
Univariate analysis assessed the distribution of respondents and their background 
demographic characteristics. Additionally, univariate analysis included prevalence of various 
barriers to ART adherence.  Bivariate analysis assessed the association between different barriers 
to adherence and demographic characteristics, perceived stress and self-efficacy. Bivariate tests 
included two tailed t test, simple linear regression, and chi square with alpha set at 0.05. 
Responses to multi-answer questions such as perceived stress, self-efficacy and barriers 
to ART adherence were added together to create a scaled response. For example, a value was 
determined for each likert scale response to each question about perceived stress and these values 
were added together to create a total perceived stress score. If a respondent answering perceived 
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stress questions answered one for question one, three for question two and one for question three, 
the total score for perceived stress would be five. This total score was used as the dependent 
variable in bivariate analysis.  
The statistical tests used to examine the research question were run in Stata.   
Results 
Descriptive 
As seen in Table 1, the sample consisted of 101 participants. Fifty percent of the sample 
is female, 50% of the sample is male. The mean age is 37.5 years (SD = 7.4). 75% of participants 
are married. 68% of participants are members of the Tumbuka ethnic group and 83% identify as 
Christian. Thirty-five percent of participants achieved education beyond primary school and 75% 
are farmers. Participants live an average of 11.4 kilometers (SD = 12.3) or 110.2 minutes (SD = 
97.7) from home to the health facility but the standard deviation indicates that the distance is 
quite varied across participants. As was intended by the inclusion criteria, participants live in 
rural areas and have limited education and economic involvement.  
 
 
 
Table 1: Distribution of sample respondent background characteristics  
(N=101 unless otherwise noted) 
 # (%) 
Location   
Lundazi 51 (50) 
Lumezi 50 (50) 
  
Age (Mean 37.5, SD 7.4)  
 <35 32 (32) 
≥35 69 (58) 
  
Gender   
Female 57 (56) 
Male 44 (44) 
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Table 1: Distribution of sample respondent background characteristics  
(N=101 unless otherwise noted) 
 # (%) 
Marital Status  
Currently Married 76 (75) 
Not Currently Married  
(Includes: divorced, separated, widowed or single) 
25 (25) 
  
Ethnic Group  
Tumbuka 69 (68) 
Not Tumbuka 
(Includes: Nsenga, Tonga, Chewa and other tribes) 
32 (32) 
  
Religious Group  
Christian 84 (83) 
Not Christian 
(Includes: Muslim, Traditional/Spiritualist, Non-religious and other) 
17 (17) 
  
Highest level of school  
Primary or less than primary 66 (65) 
More than primary 35 (35) 
  
Occupation  
Farming 76 (75) 
Not Farming 
(Includes: Trading, construction, managerial/professional, service, no occupation and other) 
25 (25) 
  
Head of household  
Yes 66 (65) 
No 35 (35) 
  
Average household income per month?  
K0-K20 46 (46) 
>K20 55 (54)  
  
Main source of drinking water for the household  
Organized 
(Includes: In dwelling, on site, public tap, borehole and well) 
85 (84)  
Natural 
(Includes: Dam/pond/stagnant and flowing/stream) 
16 (16) 
  
Main source of energy for cooking (N=99)  
Wood 87 (86) 
Not Wood 
(Includes: Electric and charcoal) 
14 (14)  
  
Main materials used for the roof of your dwelling place  
Thatch 75 (74)  
Not Thatch 26 (26) 
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Table 1: Distribution of sample respondent background characteristics  
(N=101 unless otherwise noted) 
 # (%) 
(Includes: Asbestos, plastic, corrugated iron and cement block)  
  
Description of your health in general   
Poor/Fair/Good  56 (55) 
Very good/Excellent 45 (45) 
  
From your home, approximate distance to the health facility in kilometers  
(Mean 11.4; SD 12.3) 
 
 ≤11  65 (64) 
>11 36 (36)  
  
From your home, approximate number of minutes it takes to travel to the health 
facility (Mean 110.2; SD 97.7) 
 
≤110 62 (61) 
> 110 39 (39) 
 
Barriers to Pill Taking and Clinic Attendance 
In both the barriers to clinic attendance and pill taking participant responses span the full 
available range of the scale. However, responses are highly skewed toward never experiencing 
barriers. When compiled into scale response, as described in “Analysis Plan”, the total results of 
both barriers to clinic attendance (Mean: 5.3, SD: 9.7, Range: 0-44) and pill taking (Mean: 3, 
SD: 7.7, Range: 0-44) show that the standard deviation is higher than the mean. This shows that 
there is a large variation as to whether or not there are perceived barriers to clinic attendance. 
The means barriers to both clinic attendance and pill taking are very low which demonstrates that 
most people do not perceive barriers to clinic attendance or pill taking as measured by these 
scales.  
As seen in Table 2, at least 74% of people reported never experiencing any of the barriers 
to clinic attendance. The most commonly experienced barriers to clinic attendance are related to 
access to the clinic—distance, travel expenses, and travel times. Between 13% and 18% of the 
sample reported always experiencing these barriers. Other findings that stood out in the barriers 
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to clinic attendance were that 8% of participants reported that some of the time staff are rude to 
them, 9% of the participants reported that some of the time they have to wait too long to see a 
doctor/nurse/pharmacist, and 8% reported that some of the time the clinic is too crowded.  
As seen in Table 3, at least 77% of people reported never experiencing each of the 
barriers to pill taking. 9% says they always avoid taking pills if they have to take in front of 
others. Generally, participants reported very few barriers to pill taking.  
 
Table 2: Proportion of Sample Experiencing Barriers to Clinic Attendance at Baseline (N=101) 
I do not attend my clinic appointments 
because: 
Never Rarely Some of 
the time 
Most of 
the time 
Always 
1. The clinic is too far from the bus 
stop/taxi rank  (N=100) 
75% 7% 2% 3% 13% 
2. Transport to the clinic is too expensive  74% 6% 0% 2% 18% 
3. It takes too much time to travel to and 
from the clinic. 
75% 7% 1% 1% 16% 
4. I do not want to be identified as HIV 
positive.  
82% 6% 5% 2% 5% 
5. The staff at the clinic is rude to me. 86% 5% 8% 0% 1% 
6. The staff at the clinic is impatient 
towards me 
86% 8% 5% 0% 1% 
7. There is no privacy at the clinic when I 
meet with the nurse. 
87% 7% 0% 0% 6% 
8. I cannot get time off work to do so.  85% 6% 2% 1% 6% 
9. I have to wait too long to see the doctor, 
nurse or pharmacist.  
82% 5% 9% 2% 2% 
10. I feel unsafe walking to and from the 
clinic.  
81% 6% 6% 3% 4% 
11. The clinic is too crowded.  80% 6% 8% 1% 5% 
12. There is no place where I can speak to 
a nurse or counselor without being heard 
by other people.  
91% 6% 1% 0% 2% 
Distribution - Mean: 5.3; SD: 9.7; Min: 0; Max: 44 
 
Table 3: Proportion of Sample Experiencing Barriers to Pill Taking at Baseline (N=101) 
 Never Rarely Some of 
the time 
Most of 
the time 
Always 
1. I have difficulty taking my ART pills. 
Because I do not always have food with 
which to take them.  
84% 7%  4% 2% 3% 
2. Taking my ART pills when I do not have 
food to eat makes me feel ill.  
77% 9% 4% 4% 6% 
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Table 3: Proportion of Sample Experiencing Barriers to Pill Taking at Baseline (N=101) 
 Never Rarely Some of 
the time 
Most of 
the time 
Always 
3. I do not take my pills if I have to take it 
in front of others.  
79% 8% 2% 2% 9% 
4. I do not take my pills because I do not 
have a way to remind me to take them.  
89% 6% 2% 0% 3% 
5. I forget to take my ART pills.  88% 7% 1% 1 % 3% 
6. I do not take my ART pills because the 
church pastor has told me not to.  
92% 5% 0% 0% 3% 
7. When I drink alcohol I forget to take my 
ART pills.  
91% 6% 0% 0% 3% 
8. I do not take my ART pills because I do 
not have someone to remind me to do so.  
89% 7% 1% 0% 3% 
9. I do not take my ART pills because 
traditional healing works better for me.  
92% 5% 0% 0% 3% 
10. I do not take my ART pills because I 
cannot afford the food I need to eat when I 
take them.  
90% 7% 0% 1% 2% 
11. I do not take my pills because I do not 
like taking them in front of my family.  
89% 6% 1% 0% 4% 
Distribution – Mean: 3; SD: 7.7; Min: 0; Max 44 
 
Bivariable Results 
Bivariate analysis was conducted using t-test, simple linear regression and chi-square to 
analyze the association between each background variable and the barriers to ART response 
scales.  
As seen in Table 4, there is a statistically significant association between barriers to clinic 
attendance and age (p = 0.0564). Older PLHIV experience fewer barriers to clinic attendance 
while younger PLHIV experience more barriers to clinic attendance. This finding is consistent 
with prior studies that age is inversely associated with adherence (DiMatteo, 2004). 
There was a statistically significant association between barriers to clinic attendance and 
education (p = 0.0154) (Table 4). Those with higher education reported fewer barriers, those 
with less education reported more barriers. This finding is consistent with prior studies that show 
an inverse association between adherence and education (Moomba, 2012; Yaya et al., 2014).  
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There was a statistically significant association between barriers to clinic attendance and 
minutes of travel time to the health clinic (Robust p = 0.003) (Table 4). Similar findings of a 
statistically significant association between travel time and barriers to adherence are found in 
other studies (Hardon et al., 2007; Moomba, 2012; Muya et al., 2014). While it is logical that 
distance from the clinic could be a barrier to clinic attendance, the findings did not show a 
statistically significant association between barriers to clinic attendance and distance from the 
health clinic in kilometers. Because of these findings, additional tests were run which 
dichotomized the distance from the health clinic and minutes to the health clinic, based on the 
mean, to determine if there was a statistically significant association. The robust dichotomized 
distance in kilometers to the health facility was found to be statistically significant (p = 0.031) 
indicating that those who travel fewer than 11 kilometers to the health clinic face fewer barriers 
to clinic attendance than those who travel more than 11 kilometers to the clinic.  
Existential dimensions (meaning, self-determination and quality of life) play a key role in 
adherence and are often overlooked in research (Wright, 2000). Studies vary in their results of 
self-efficacy as a predictor of ART adherence (Wright, 2000). As seen in Table 4, the findings in 
this study show a statistically significant association between ART treatment self-efficacy and 
barriers to clinic attendance (p = 0.0009). This means that those with higher levels of self-
efficacy reported fewer barriers to clinic attendance. Self-efficacy was not significantly 
associated with barriers to pill taking.  
Self-perceived health was significantly associated with barriers to pill taking (p = 0.055). 
ART patients with better self-perceived health reported fewer barriers to pill taking compared to 
ART patients with poor self-perceived health.  
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Table 4: Bivariable analysis of patient characteristics and barriers to clinic attendance & pill taking  
 Barriers to Clinic 
Attendance 
Barriers to Pill 
Taking  
Age (<35/≥35) *p = 0.0564 P = 0.5734 
   
Gender (Male/Female) p = 0.5648 p = 0.8478 
   
Marital Status (Currently Married/Not Currently 
Married) 
p = 0.3758 p = 0.6595 
   
Ethnic Group (Tumbuka/Not Tumbuka) p = 0.2882 p = 0.4764 
   
Religious Group (Christian/Not Christian) p = 0.1198 p = 0.5774 
   
Highest level of school (Primary or less than 
primary/More than primary) 
*p = 0.0154 p = 0.3333 
   
Occupation (Farming/Not Farming) p = 0.1059 p = 0.6813 
   
Head of household (Yes/No) p = 0.4215 p = 0.5944 
   
Average monthly household income (K0-K20/>K20) p = 0.0899 p = 0.6514  
   
Main source of drinking water for the household 
(Organized/Natural) 
p = 0.1153 p = 0.4403  
   
Main source of energy for cooking (Wood/Not 
wood) 
p = 0.0845 p = 0.1163 
   
Main materials used for the roof of your dwelling 
place (Thatch/Not Thatch) 
p = 0.6718 p = 0.1956 
   
Description of your health in general 
(Poor/Fair/Good vs. Very good/Excellent) 
p = 0.1711 *p = 0.055 
   
Distance from your home to the health facility in 
kilometers  
  
With outliers (70km x 2) p = 0.669 p = 0.112 
Robust p = 0.504 p = 0.179 
   
Dichotomized ≤ 11/ >11 p = 0.17 p = 0.228   
Robust *p = 0.031 p = 0.143  
   
Distance from your home to the health facility in 
minutes  
  
Regular *p= 0.009 p = 0.908 
Regular Robust *p=0.003 p = 0.946 
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Table 4: Bivariable analysis of patient characteristics and barriers to clinic attendance & pill taking  
 Barriers to Clinic 
Attendance 
Barriers to Pill 
Taking  
Dichotomized ≤110/>110 *p = 0.021 p = 0.684 
Dichotomized Robust *p = 0.027 p = 0.701 
   
ART Treatment Adherence Self-Efficacy *p = 0.0009 p = 0.385 
   
Perceived Stress p = 0.086 p = 0.081 
   
 
Discussion 
Discussion  
The results of this study are important because they indicate that most people are not 
experiencing barriers to clinic attendance and pill taking as measured by these scales (Tables 2 & 
3). This does not mean that adherence is not a challenge for some patients but instead suggests 
that interventions should be thoughtfully targeted to those people who require additional support 
in overcoming barriers to clinic attendance and pill taking.  
Some of the specific barriers are discussed below: 
ART interventions should be designed to reach rural population. As seen in Table 2, 
distance and travel time are the most perceived barriers to clinic attendance, which is particularly 
significant for rural populations.  
The fact that 9% of people always avoid taking pills in front of others means that 
although there are few barriers to pill taking, there are still challenges with stigma. Reduction of 
stigma is a social change that takes time but could have a profound impact on communities in 
terms of increasing adherence to also decrease ART resistance.  
Although research has mixed findings on the association between age and adherence, this 
study shows that there is a statistically significant association between age and barriers to clinic 
attendance. Due to their youth, young people are more likely to spend a long time on ART so 
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their adherence is of particular concern to ensure that they do not run out of ART options if they 
encounter resistance. More research is needed to focus on determining the most effective 
intervention for young people.  
Existential dimensions (meaning, self-determination and quality of life) were not the 
focal point of the study and yet they produced some of the strongest results. The findings 
demonstrate a statistically significant association between ART treatment self-efficacy and 
barriers to clinic attendance (p = 0.0009). It is unclear whether those who feel confident to 
adhere to ART report fewer barriers or if fewer barriers lead to a confidence to take ART. Future 
research is needed to clarify results and determine whether targeted self-efficacy interventions 
could have an impact on increasing ART adherence.  
A topic not explored in this study that could be investigated in further research is the 
relationship between barriers to adherence and ART attrition as some research shows that 
barriers lead to attrition (Musheke et al., 2012). Estimates suggest that only 60% of patients 
continue ART after 2 years for reasons similar to the barriers to clinic attendance and pill taking 
examined here (Musheke et al., 2012). Traditional complementary and alternative medicines as 
well as religious beliefs are among factors that have been shown to predict attrition and should 
be part of further research (Moomba, 2012; Musheke et al., 2012).  
Implications  
ART adherence should be improved to increase positive heath outcomes for persons 
living with HIV as well as to reduce ART resistance and transmission of HIV. However, 
achieving 100% ART adherence is not realistic (Wright, 2000). Therefore, it’s also important to 
invest in early HIV diagnosis, ART access and delivery, as well as long term care (Lawn et al., 
2008).  
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The results of this study can provide useful insights into targeted interventions. Because 
the barriers to clinic attendance are greater than those of pill taking, it is best to invest energies in 
reducing barriers to clinic attendance. Multi dimensional interventions that target individual 
needs are recommended (Wright, 2000). A strategy such as increased refill times (3 months 
instead of 1) are recommended to decrease the number of times patients need to overcome 
barriers to clinic attendance (Hardon et al., 2007). Alternatively, some ART delivery models 
utilize a home-based care system to reach resource-limited rural environments (Weidle, et al. 
2006). Increased accessed to education or interventions that target self-efficacy could also have 
an impact on reported barriers to clinic attendance.  
Limitations 
The sample size for this study is small which may limit power and ability to detect 
effects. A larger sample size may have provided more statistically significant findings. However, 
the fact that there were many non-statistically significant findings is not dissimilar from the 
literature which, says that there is not one combination of predictors or barriers to pill taking and 
clinic attendance (Wright, 2000).  
Another limitation for this research is the possibility for response bias from the 
respondents. Individuals may have misremembered their ART regimen practices or responded 
with answers designed to please the interviewer. Additionally, questions such as those about 
distance assume accuracy of time keeping or distance awareness and may have created 
unintentional response bias. Though the study design intended to minimize this bias, it cannot be 
avoided completely.   
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